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If you implant an 8-cell human
embryo in the womb, it may or
may not result in the development
of a foetus and birth of a baby. If
you flush the embryos left over
after IVF treatment down the sink,
that’s perfectly fine. But if you do
anything else with them, you’re
certain to generate legal problems
that can turn out very differently
depending on where you are, and
under whose legislation you work.
Laws on embryo protection are
very different between countries,
and often contradictory within
one. The UK’s Human
Fertilisation and Embryology
Authority (HFEA), for instance,
made the headlines in early June
in two unrelated cases, whose
outcomes were reported within a
week of each other, by pure
coincidence. In one case, the
authority allowed a state-funded
research institute to proceed with
research that must not receive
government funding in the US. In
the other, a couple received
treatment in the US which the
HFEA had denied them.
The latter case is that of the
Whittaker family, whose four-year-
old, Charlie, has a rare kind of
anaemia. They wanted further
children in any case, but in order
to improve the likelihood that the
new baby’s umbilical cord might
help cure Charlie’s disease, they
applied to the HFEA for permission
to select a tissue-matched
embryo. The authority had, after
all, approved a similar application
from the Hashmi family, who are
trying to save their son Zain
Hashmi from almost certain death.
Unlike the Whittakers, the Hashmis
had already a bunch of children
(partially as a result of trying for a
tissue match the natural way), so
they were criticized from some
quarters for trying to produce the
selected baby only for Zain’s sake.
The HFEA, however, did not
consider the question ‘for whose
sake’ a child was going to be
created. Their main criterion was
whether or not the proposed pre-
implantation diagnosis (PID) of the
embryos — involving as it does the
risk that the removal of one of the
eight undifferentiated cells might
cause problems in ways as yet
unknown — served the baby to be
born or whether it served only the
sibling to be cured. Zain Hashmi’s
disorder is genetic, so there is — in
the eyes of the HFEA — a valid
reason for the use of PID, to make
sure the new Hashmi baby is free
of Zain’s disease. And while this
analysis is done anyway, the
authority does not particularly mind
the tissue-matching being done as
well. Charlie Whittaker’s problem,
however is not genetic and so, in
his case, the embryo suffers the
loss of a cell for reasons that only
benefit Charlie, not the birth of a
healthy new baby.
The birth of a baby selected to be a potential stem cell donor for a sick
brother pushes on the fast-developing and still contentious debate on
what are the goals of stem cell research and the political boundaries
that constrain its development. Michael Gross reports. 
In the spotlight: A British mother defends her decision to select a baby that is a poten-
tial stem-cell donor to its sick brother under full media glare and a growing debate
about how such developments should be regulated.
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While this argument appeared
to be vaguely logical and
consolidated the role of the
authority which had earlier ruled
that such cases must be decided
one by one on individual apects,
the Whittakers did not take no for
an answer. They followed the
example of Diane Blood, who
travelled to Belgium in order to
have a baby from her deceased
husband’s frozen sperm, and
went abroad. Although they are
being looked after by the London-
based IVF expert Mohammed
Taranissi, the Whittakers had
parts of their selection/IVF
procedure carried out at a
Chicago clinic to avoid legal
complications in Britain. Out of
nine embryos produced, two
tissue-matched ones were
implanted, one of which resulted
in the birth of Jamie Whittaker —
back in England — on June 16th.
While parents trek to the Land
of the Free for embryo selection
treatment, some researchers have
travelled in the opposite direction
due to their frustration with the
tight restrictions on embryo
research. Most famously, Roger
Pedersen moved from the
University of California at San
Francisco to Cambridge
University for this reason. The
Bush administration has ruled that
no government funding can be
given to any research involving
human embryos, and no new lines
of embryonic stem cells may be
produced in the US. There is a list
of known stem cell lines, many of
them produced in countries with
more liberal regulations such as
Israel, which researchers are
allowed to use.
Meanwhile, on the other side of
the Atlantic, the HFEA has
highlighted its more open if still
cautious approach to embryo
research by granting the Roslin
Institute — the place where Dolly
the sheep was cloned — a one-
year permission to generate
human embryonic stem cells from
embryos left over after IVF
treatment, with the informed
consent of the embryo donors.
The institute will also be allowed
to stimulate unfertilized egg cells
into embryonal development, a
process known as
parthenogenesis. For the Roslin
institute, whose main expertise is
in the embryology and cloning of
mammals, this may be a first step
into the promising domain of
medical applications derived from
human stem cells. Studies of early
human embryos, combined with
the vast body of experience the
institute has gathered with other
mammals, could also serve to
improve the understanding of
some of the complications and
difficulties in early pregnancy.
Seeing that even the Roslin
Institute with its solid reputation in
research in this field was only
granted a license for the limited
period of one year, it is clear that
the HFEA is juggling the demands
of research progress and the
worries of people afraid of the
brave new world of stem cells and
selected embryos. The authority
was set up in 1991 as a
consequence of the 1990 Human
Fertilisation and Embryology Act,
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Stem-cell licence: The Roslin Institure near Edinburgh, famous for the creation of the cloned but now deceased sheep Dolly shown
here with researcher Ian Wilmuut, has won short-term approval for work on human stem cells with the hope of developing their use
in medical applications. (Photograph: Science Photo Library).
and it is required by law to keep
an eye on any human embryo
created in any other way than by
the natural proceedings.
In December 2002, the High
Court seriously undermined the
HFEA’s position when it decided
that its ruling that allowed the
Hashmi family to use embryo
selection had exceeded its legal
powers. In May, however, the
appeal court overturned that
judgment and cleared the last
legal hurdle for the Hashmis.
Even if the campaigners
opposing their treatment take the
case to the House of Lords, the
Hashmis can proceed with their
treatment.
All this goes to show that a
specialised authority like the
HFEA, which supervises all
embryo-related activities and
makes individual judgements in
those especially tricky cases that
make the headlines, is a very
useful thing to have, but that it
may run into serious problems if
the legislation does not keep up
with scientific progress. The law
that brought the HFEA into
existence is 13 years old, a
timespan in which the
reproduction field has changed
beyond recognition.
Next to keeping up with the
fast-moving technical
possibilities, the biggest challenge
is international coordination.
Currently, religious views still
determine what can be done
where. The Jewish faith doesn’t
count the embryo as a human
being, so Israel is a paradise for
people who want to produce stem
cells. At the other end of the
spectrum, the strong influence of
Christian fundamentalism on US
politics makes stem cell research
more and more difficult in the
United States. Until politicians are
willing to accept the assessment
of scientific developments without
religious prejudice, both
researchers and families in need
of advanced treatment will
probably continue to vote with
their feet.
Michael Gross is a science writer in
residence at the school of
crystallography, Birkbeck College,
University of London. He can be
contacted via his web page at
www.proseandpassion.com
It’s not every day that scientists
offer themselves up as ‘straight
men,’ to lay the groundwork for the
perfect joke. David Page and his
colleagues performed this duty
admirably in the pages of Nature.
The subject, naturally, was sex — or
close enough: sex chromosomes.
Page, a Howard Hughes scholar
at the Whitehead Institute and MIT,
and his happy band performed a
rather amazing feat. They waded
through the terrifying tangle of DNA
that is the human Y chromosome
and they actually made sense of it.
Not even the exalted fly guys, the
Drosophila sequencers, could
claim this treasure. Page and
company deciphered the essence
of man. And when they were done,
they had quite the story to tell
about a remarkable trick of nature.
Naturally, not everybody went
for the highbrow angle on this
story. Take The Australian, for
instance, which teed off under a
headline declaring that ‘It’s puny
in men’s genes.’
‘Geneticists have finally
confirmed what women have
known for generations. The male-
making Y chromosome is puny
and full of genetic gibberish. The
unsettling news for men comes
today as a team of scientists
report in the journal Nature that
they have nailed down all the
chemical building blocks, or
bases, of the 78 genes unique to
the “male-specific’’ region of the Y
chromosome.’
The British press also seized
the moment to capitalize on the
delicious opportunities afforded
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Mediawatch: Richard F. Harris looks at the response to the analysis of
the male-specific genes on the human Y chromosome and finds many
commentators less than impressed about what contitutes human
maleness.
Not X rated: the diminutive human Y chromosome (right) is dwarfed by its X chromo-
some partner in males (shown left ) in this scanning electron microscope image.
(Photograph: Science Photo Library). 
